...
bcyc-img

Bicycle Therapeutics Ltd, Common Stock

BCYC

NSQ

$13.81

-$6.3

(-31.33%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.46B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
5.71M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.89
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$12.17 L
$28.67 H
$13.81

About Bicycle Therapeutics Ltd, Common Stock

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBCYCSectorS&P500
1-Week Return-30.78%-2.27%-0.57%
1-Month Return-40.53%-3.96%1.21%
3-Month Return-48.89%-9.7%7.57%
6-Month Return-43.17%-3.37%11.45%
1-Year Return-16.15%3.71%28.48%
3-Year Return-73.94%3.8%29.52%
5-Year Return77.05%39.78%90.66%
10-Year Return15.08%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue13.80M10.39M11.70M14.46M26.98M[{"date":"2019-12-31","value":51.16,"profit":true},{"date":"2020-12-31","value":38.52,"profit":true},{"date":"2021-12-31","value":43.36,"profit":true},{"date":"2022-12-31","value":53.61,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue25.54M33.15M44.88M3.69M6.47M[{"date":"2019-12-31","value":56.91,"profit":true},{"date":"2020-12-31","value":73.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":8.21,"profit":true},{"date":"2023-12-31","value":14.41,"profit":true}]
Gross Profit13.80M(22.76M)(33.18M)10.78M20.51M[{"date":"2019-12-31","value":67.29,"profit":true},{"date":"2020-12-31","value":-110.97,"profit":false},{"date":"2021-12-31","value":-161.8,"profit":false},{"date":"2022-12-31","value":52.54,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%(219.05%)(283.69%)74.51%76.03%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-219.05,"profit":false},{"date":"2021-12-31","value":-283.69,"profit":false},{"date":"2022-12-31","value":74.51,"profit":true},{"date":"2023-12-31","value":76.03,"profit":true}]
Operating Expenses40.10M62.35M77.31M131.12M216.92M[{"date":"2019-12-31","value":18.49,"profit":true},{"date":"2020-12-31","value":28.74,"profit":true},{"date":"2021-12-31","value":35.64,"profit":true},{"date":"2022-12-31","value":60.44,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(26.30M)(51.96M)(65.62M)(116.65M)(189.95M)[{"date":"2019-12-31","value":-2629900000,"profit":false},{"date":"2020-12-31","value":-5196000000,"profit":false},{"date":"2021-12-31","value":-6561800000,"profit":false},{"date":"2022-12-31","value":-11665300000,"profit":false},{"date":"2023-12-31","value":-18994600000,"profit":false}]
Total Non-Operating Income/Expense(3.75M)452.00K(5.73M)4.82M21.48M[{"date":"2019-12-31","value":-17.46,"profit":false},{"date":"2020-12-31","value":2.1,"profit":true},{"date":"2021-12-31","value":-26.67,"profit":false},{"date":"2022-12-31","value":22.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(30.86M)(51.73M)(68.48M)(114.24M)(179.21M)[{"date":"2019-12-31","value":-3086200000,"profit":false},{"date":"2020-12-31","value":-5173400000,"profit":false},{"date":"2021-12-31","value":-6848200000,"profit":false},{"date":"2022-12-31","value":-11424100000,"profit":false},{"date":"2023-12-31","value":-17920700000,"profit":false}]
Income Taxes(254.00K)(724.00K)(1.66M)(1.52M)1.46M[{"date":"2019-12-31","value":-17.43,"profit":false},{"date":"2020-12-31","value":-49.69,"profit":false},{"date":"2021-12-31","value":-114.14,"profit":false},{"date":"2022-12-31","value":-104.6,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(30.61M)(51.01M)(66.82M)(112.72M)(180.66M)[{"date":"2019-12-31","value":-3060800000,"profit":false},{"date":"2020-12-31","value":-5101000000,"profit":false},{"date":"2021-12-31","value":-6681900000,"profit":false},{"date":"2022-12-31","value":-11271700000,"profit":false},{"date":"2023-12-31","value":-18066400000,"profit":false}]
Income From Continuous Operations(30.61M)(51.01M)(66.82M)(112.72M)(180.66M)[{"date":"2019-12-31","value":-3060800000,"profit":false},{"date":"2020-12-31","value":-5101000000,"profit":false},{"date":"2021-12-31","value":-6681900000,"profit":false},{"date":"2022-12-31","value":-11271700000,"profit":false},{"date":"2023-12-31","value":-18066400000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(30.61M)(51.01M)(66.82M)(112.72M)(180.66M)[{"date":"2019-12-31","value":-3060800000,"profit":false},{"date":"2020-12-31","value":-5101000000,"profit":false},{"date":"2021-12-31","value":-6681900000,"profit":false},{"date":"2022-12-31","value":-11271700000,"profit":false},{"date":"2023-12-31","value":-18066400000,"profit":false}]
EPS (Diluted)(3.41)(2.65)(2.69)(3.80)(5.13)[{"date":"2019-12-31","value":-341,"profit":false},{"date":"2020-12-31","value":-265,"profit":false},{"date":"2021-12-31","value":-269,"profit":false},{"date":"2022-12-31","value":-380,"profit":false},{"date":"2023-12-31","value":-513,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BCYC
Cash Ratio 15.79
Current Ratio 17.13
Quick Ratio 18.16

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BCYC
ROA (LTM) -15.02%
ROE (LTM) -26.67%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BCYC
Debt Ratio Lower is generally better. Negative is bad. 0.17
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.83

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BCYC
Trailing PE NM
Forward PE NM
P/S (TTM) 39.47
P/B 1.75
Price/FCF NM
EV/R 15.62
EV/Ebitda NM

FAQs

What is Bicycle Therapeutics Ltd share price today?

Bicycle Therapeutics Ltd (BCYC) share price today is $13.81

Can Indians buy Bicycle Therapeutics Ltd shares?

Yes, Indians can buy shares of Bicycle Therapeutics Ltd (BCYC) on Vested. To buy Bicycle Therapeutics Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BCYC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Bicycle Therapeutics Ltd be purchased?

Yes, you can purchase fractional shares of Bicycle Therapeutics Ltd (BCYC) via the Vested app. You can start investing in Bicycle Therapeutics Ltd (BCYC) with a minimum investment of $1.

How to invest in Bicycle Therapeutics Ltd shares from India?

You can invest in shares of Bicycle Therapeutics Ltd (BCYC) via Vested in three simple steps:

  • Click on Sign Up or Invest in BCYC stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Bicycle Therapeutics Ltd shares
What is Bicycle Therapeutics Ltd 52-week high and low stock price?

The 52-week high price of Bicycle Therapeutics Ltd (BCYC) is $28.67. The 52-week low price of Bicycle Therapeutics Ltd (BCYC) is $12.17.

What is Bicycle Therapeutics Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Bicycle Therapeutics Ltd (BCYC) is

What is Bicycle Therapeutics Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Bicycle Therapeutics Ltd (BCYC) is 1.75

What is Bicycle Therapeutics Ltd dividend yield?

The dividend yield of Bicycle Therapeutics Ltd (BCYC) is 0.00%

What is the Market Cap of Bicycle Therapeutics Ltd?

The market capitalization of Bicycle Therapeutics Ltd (BCYC) is $1.46B

What is Bicycle Therapeutics Ltd’s stock symbol?

The stock symbol (or ticker) of Bicycle Therapeutics Ltd is BCYC

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top